These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 24531207)

  • 21. FDA and EMEA pool scientific advice.
    Katsnelson A
    Nat Biotechnol; 2004 Dec; 22(12):1490-1. PubMed ID: 15583642
    [No Abstract]   [Full Text] [Related]  

  • 22. Communicating with the FDA: the "third rail" of a new model for drug development.
    Stanski DR; Orloff JJ
    J Clin Pharmacol; 2008 Feb; 48(2):144-5. PubMed ID: 18199890
    [No Abstract]   [Full Text] [Related]  

  • 23. Concise Review: The U.S. Food and Drug Administration and Regenerative Medicine.
    Witten CM; McFarland RD; Simek SL
    Stem Cells Transl Med; 2015 Dec; 4(12):1495-9. PubMed ID: 26494784
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FDA appointment is stalled as revelations emerge over Plan B.
    Tanne JH
    BMJ; 2006 Aug; 333(7563):317. PubMed ID: 16902205
    [No Abstract]   [Full Text] [Related]  

  • 25. Trying times at the FDA--the challenge of ensuring the safety of imported pharmaceuticals.
    Schweitzer SO
    N Engl J Med; 2008 Apr; 358(17):1773-7. PubMed ID: 18434648
    [No Abstract]   [Full Text] [Related]  

  • 26. Relocating abroad. FDA sends staff overseas to help monitor imports.
    Lee J
    Mod Healthc; 2011 Oct; 41(43):32. PubMed ID: 22111150
    [No Abstract]   [Full Text] [Related]  

  • 27. The FDA as a public health agency.
    Hamburg MA; Sharfstein JM
    N Engl J Med; 2009 Jun; 360(24):2493-5. PubMed ID: 19470577
    [No Abstract]   [Full Text] [Related]  

  • 28. The implications of "advanced therapies" regulation.
    Sethe SC
    Rejuvenation Res; 2010; 13(2-3):327-8. PubMed ID: 20462386
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FDA challenges stem-cell clinic.
    Cyranoski D
    Nature; 2010 Aug; 466(7309):909. PubMed ID: 20725009
    [No Abstract]   [Full Text] [Related]  

  • 30. What ails the FDA?
    Okie S
    N Engl J Med; 2005 Mar; 352(11):1063-6. PubMed ID: 15784660
    [No Abstract]   [Full Text] [Related]  

  • 31. Autologous cell therapies: challenges in US FDA regulation.
    McAllister TN; Audley D; L'Heureux N
    Regen Med; 2012 Nov; 7(6 Suppl):94-7. PubMed ID: 23210819
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FDA's proposed regulatory approach to regulation of hematopoietic stem/progenitor cell products.
    Harvath L
    Cytotherapy; 1999; 1(4):358-9. PubMed ID: 20440912
    [No Abstract]   [Full Text] [Related]  

  • 33. FDA's expanding postmarket authority to monitor and publicize food and consumer health product risks: the need for procedural safeguards to reduce "transparency" policy harms in the post-9/11 regulatory environment.
    Roller ST; Pippins RR; Ngai JW
    Food Drug Law J; 2009; 64(3):577-98. PubMed ID: 19999646
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug safety reform at the FDA--pendulum swing or systematic improvement?
    McClellan M
    N Engl J Med; 2007 Apr; 356(17):1700-2. PubMed ID: 17435081
    [No Abstract]   [Full Text] [Related]  

  • 35. An FDA perspective on preclinical development of cell-based regenerative medicine products.
    Bailey AM; Mendicino M; Au P
    Nat Biotechnol; 2014 Aug; 32(8):721-3. PubMed ID: 25093890
    [No Abstract]   [Full Text] [Related]  

  • 36. New office and new leader aim to streamline FDA cancer drug review process.
    Twombly R
    J Natl Cancer Inst; 2005 May; 97(10):708-9. PubMed ID: 15900036
    [No Abstract]   [Full Text] [Related]  

  • 37. Considerations for tissue-engineered and regenerative medicine product development prior to clinical trials in the United States.
    Lee MH; Arcidiacono JA; Bilek AM; Wille JJ; Hamill CA; Wonnacott KM; Wells MA; Oh SS
    Tissue Eng Part B Rev; 2010 Feb; 16(1):41-54. PubMed ID: 19728784
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Playing "kick the FDA"--risk-free to players but hazardous to public health.
    Wood AJ
    N Engl J Med; 2008 Apr; 358(17):1774-5. PubMed ID: 18434649
    [No Abstract]   [Full Text] [Related]  

  • 39. Regulatory requirements of the Food and Drug Administration would preclude product claims based on observational research.
    Griffin JP; Godfrey BM; Sherman RE
    Health Aff (Millwood); 2012 Oct; 31(10):2188-92. PubMed ID: 23048095
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Making a difference.
    Nat Biotechnol; 2009 Apr; 27(4):297. PubMed ID: 19352347
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.